BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 23291073)

  • 1. [A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
    Zhao WY; Chen DY
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):775-9. PubMed ID: 23291073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
    Han JY; Lee DH; Song JE; Lee SY; Kim HY; Kim HT; Lee JS
    Cancer; 2008 Jul; 113(2):388-95. PubMed ID: 18484595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.
    Han JY; Lee GK; Lim KY; Lee YJ; Nam BH; Lee JS
    Cancer Res Treat; 2017 Jul; 49(3):678-687. PubMed ID: 27737534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A randomized trial of docetaxol plus cisplatin versus gemzar plus cisplatin in treating advanced non-small cell lung cancer].
    Gao Y; Shi ZQ; Cao CW; Zhu CL; Guo J
    Ai Zheng; 2005 Aug; 24(8):985-9. PubMed ID: 16086878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
    Ohe Y; Ohashi Y; Kubota K; Tamura T; Nakagawa K; Negoro S; Nishiwaki Y; Saijo N; Ariyoshi Y; Fukuoka M
    Ann Oncol; 2007 Feb; 18(2):317-23. PubMed ID: 17079694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.
    Georgoulias V; Agelidou A; Syrigos K; Rapti A; Agelidou M; Nikolakopoulos J; Polyzos A; Athanasiadis A; Tselepatiotis E; Androulakis N; Kalbakis K; Samonis G; Mavroudis D
    Br J Cancer; 2005 Oct; 93(7):763-9. PubMed ID: 16175189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study.
    Pectasides D; Mylonakis N; Farmakis D; Nikolaou M; Koumpou M; Katselis I; Gaglia A; Kostopoulou V; Karabelis A; Kosmas C
    Anticancer Res; 2003; 23(5b):4205-11. PubMed ID: 14666626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
    Zhang L; Zhang Y; Li N; Xu F; Pan ZK; Guan ZZ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1455-8. PubMed ID: 15566656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A randomized comparative trial of three combined regimens containing cisplatin for treatment of advanced non-small cell lung cancer].
    Liu L; Wang XW; Li L; Zhang X; Zhang WD; Yu XJ
    Ai Zheng; 2006 Aug; 25(8):990-4. PubMed ID: 16965680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
    Georgoulias V; Kouroussis C; Agelidou A; Boukovinas I; Palamidas P; Stavrinidis E; Polyzos A; Syrigos K; Veslemes M; Toubis M; Ardavanis A; Tselepatiotis E; Vlachonikolis I;
    Br J Cancer; 2004 Aug; 91(3):482-8. PubMed ID: 15238986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
    Hu X; Jiao S; Zhang S; Wang Z; Wang M; Huang C; Zheng R; Li K; Wang J; Wang Y; Ouyang X; Lv W; Cheng G; Hu C; Luo R; Sun Y
    Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):569-75. PubMed ID: 23075680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.
    Han JY; Nam BH; Kim HY; Yoon SJ; Kim HT; Lee JS
    Ann Oncol; 2012 Nov; 23(11):2925-2930. PubMed ID: 22782331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
    Nakamura Y; Soda H; Oka M; Kinoshita A; Fukuda M; Fukuda M; Takatani H; Nagashima S; Soejima Y; Kasai T; Nakatomi K; Masuda N; Tsukamoto K; Kohno S
    J Thorac Oncol; 2011 Jan; 6(1):121-7. PubMed ID: 21150467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
    Rocha Lima CM; Rizvi NA; Zhang C; Herndon JE; Crawford J; Govindan R; King GW; Green MR;
    Ann Oncol; 2004 Mar; 15(3):410-8. PubMed ID: 14998842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
    Zatloukal P; Petruzelka L; Zemanová M; Kolek V; Skricková J; Pesek M; Fojtů H; Grygárková I; Sixtová D; Roubec J; Horenková E; Havel L; Průsa P; Nováková L; Skácel T; Kůta M
    Lung Cancer; 2003 Sep; 41(3):321-31. PubMed ID: 12928123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
    Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.